(0.27%) 5 105.25 points
(0.60%) 38 614 points
(0.60%) 17 756 points
(0.37%) $79.24
(-0.79%) $2.02
(0.31%) $2 316.80
(0.60%) $26.99
(0.56%) $968.00
(-0.09%) $0.931
(-0.14%) $10.98
(-0.16%) $0.797
(0.87%) $91.92
5 days till quarter result
(amc 2024-05-08)
Expected move: +/- 11.19%
@ $38.32
Utstedt: 14 feb 2024 @ 21:08
Avkastning: -30.79%
Forrige signal: feb 13 - 21:48
Forrige signal:
Avkastning: -0.52 %
Live Chart Being Loaded With Signals
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States...
Stats | |
---|---|
Dagens volum | 692 569 |
Gjennomsnittsvolum | 501 903 |
Markedsverdi | 713.79M |
EPS | $0 ( 2024-03-07 ) |
Neste inntjeningsdato | ( $-1.170 ) 2024-05-08 |
Last Dividend | $0.0596 ( 2013-01-08 ) |
Next Dividend | $0 ( N/A ) |
P/E | -23.68 |
ATR14 | $0.0460 (0.17%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Chivukula Pad | Sell | 17 435 | Common Stock |
2024-03-19 | Chivukula Pad | Sell | 8 565 | Common Stock |
2023-12-15 | Sassine Andy | Buy | 75 000 | Employee Stock Option (right to buy) |
2023-12-15 | Chivukula Pad | Buy | 125 000 | Employee Stock Option (right to buy) |
2023-12-15 | Kurata Lance | Buy | 75 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
77.94 |
Last 97 transactions |
Buy: 2 555 134 | Sell: 1 046 972 |
Volum Korrelasjon
Arcturus Therapeutics Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
AVEO | 0.955 |
ITMR | 0.949 |
RBNC | 0.939 |
HEAR | 0.932 |
SUMR | 0.929 |
FCBP | 0.92 |
DVCR | 0.92 |
RMRM | 0.918 |
AMYT | 0.917 |
EA | 0.917 |
10 Mest negative korrelasjoner | |
---|---|
SBNY | -0.929 |
IMV | -0.925 |
DPRO | -0.92 |
NDRA | -0.913 |
MNDO | -0.91 |
CLDX | -0.909 |
SSPK | -0.909 |
WABC | -0.908 |
DFFN | -0.907 |
TCBC | -0.907 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Arcturus Therapeutics Korrelasjon - Valuta/Råvare
Arcturus Therapeutics Økonomi
Annual | 2023 |
Omsetning: | $157.75M |
Bruttogevinst: | $154.79M (98.13 %) |
EPS: | $-1.120 |
FY | 2023 |
Omsetning: | $157.75M |
Bruttogevinst: | $154.79M (98.13 %) |
EPS: | $-1.120 |
FY | 2022 |
Omsetning: | $205.76M |
Bruttogevinst: | $62.70M (30.48 %) |
EPS: | $0.350 |
FY | 2021 |
Omsetning: | $12.36M |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-7.74 |
Financial Reports:
No articles found.
Arcturus Therapeutics Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0200 | 2012-03-06 |
Last Dividend | $0.0596 | 2013-01-08 |
Next Dividend | $0 | N/A |
Payout Date | 2013-01-15 | |
Next Payout Date | N/A | |
# dividends | 12 | -- |
Total Paid Out | $0.679 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.12 | -- |
Div. Sustainability Score | 1.571 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0 | 0.00% |
2013 | $0.119 | 0.23% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.165 | 1.500 | -3.31 | -4.96 | [0 - 0.5] |
returnOnAssetsTTM | -0.0619 | 1.200 | -2.06 | -2.48 | [0 - 0.3] |
returnOnEquityTTM | -0.0907 | 1.500 | -2.12 | -3.18 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.72 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.62 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 4.23 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0704 | -1.500 | 8.83 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -92.63 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.677 | 2.00 | -0.226 | -0.451 | [0 - 30] |
freeCashFlowPerShareTTM | -0.784 | 2.00 | -0.392 | -0.784 | [0 - 20] |
debtEquityRatioTTM | 0.108 | -1.500 | 9.57 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.341 | 1.000 | 7.65 | 7.65 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.442 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.596 | 1.000 | -4.42 | -4.42 | [0.2 - 2] |
assetTurnoverTTM | 0.375 | 0.800 | -0.836 | -0.668 | [0.5 - 2] |
Total Score | 1.571 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -27.95 | 1.000 | -2.92 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0907 | 2.50 | -1.362 | -3.18 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.784 | 2.00 | -0.261 | -0.784 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.677 | 2.00 | -0.226 | -0.451 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.112 | 1.000 | -5.30 | 0 | [0.1 - 0.5] |
Total Score | -1.760 |
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.